Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3909-3917

  Smit, Egbert F ^a   Van Meerbeeck, Jan P A M ^a   Lianes, Pilar ^a   Debruyne, Channa ^a   Legrand, Catherine ^a   Schramel, Franz ^a   Smit, Hans ^a   Gaafar, Rabab ^a   Biesma, Bonne ^a   Manegold, Chris ^a   Neymark, Niels ^a   Giaccone, Giuseppe ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EUROPE; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0346560025     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.195     Document Type: Article

References (44)

1. Parker DM, Whelan SL, Ferlay J, et al: Cancer Incidence in Five Continents. IARC scientific publications, vol 143. Lyon, France, International Agency for Research on Cancer, 1997
2. Page NC, Read WL, Tierney RM, et al: The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 21:305a, 2002 (abstr 1216)
3. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non small cell lung cancer: A meta analysis. Lancet 342:19-21, 1993
4. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
5. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
6. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074-1080,2000
7. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. Br J Cancer 83:447-453, 2000
8. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-smal-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
9. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
10. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
11. Giaccone G, Splinter TAW, DeBruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16:2133-2141, 1998
12. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12-18, 1999
13. Crino L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522-3530, 1999
14. Earle CC, Evans WK: Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 80:815-820, 1999
15. Lees M, Aristides M, Maniadakis N, et al: Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of non small cell lung cancer. Pharmacoeconomics 20:325-337, 2002
16. Annemans L, Giaccone G, Vergenegre A: The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: A multicountry analysis. Anticancer Drugs 10:605-615, 1999
17. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
18. Leudke DW, Einhorn L, Ommara GA, et al: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small-cell lung cancer: A Southern Cancer Study Group trial. J Clin Oncol 8:886-891, 1990
19. Gridelli C, Perrone F, Palmeri S, et al: Mitomycin plus vindesine plus etoposide (MEV) versus mitomycin plus vindesine plus cisplatin (MVP) in stage IV non-small-cell-lung cancer: A phase III multicentre randomized trial. Ann Oncol 7:821-826, 1996
20. Giaccone G, Smit EF, Van Meerbeeck JPAM, et al: A phase I/II study of gemcitabine and paclitaxel in advanced non-small cell lung cancer patients. Ann Oncol 11:109-112, 2000
21. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
22. World Health Organization: Handbook for Reporting Results of Cancer Treatment-Publication no 48. Geneva, Switzerland, World Health Organization, 1979
23. NCIC-CTC grading system. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
24. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
25. George SL: The required size and length of a phase III clinical trial, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford Medical Publications, 1998, pp 287-311
26. Lann KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrica 70:659-663, 1983
27. O'Brian PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
30. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
31. Payers P, Aaronson N, Bjordal K, et al: EORTC QLQ Scoring Manual (ed 3). Brussels, Belgium, European Organization for Research and Treatment of Cancer, 2001
32. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
33. Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 357:1478-1484, 2001
34. Kosmidis PA, Mylonakis N, Nicolaides C, et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 20:3578-3585, 2002
35. Gridelli C, Shepherd F, Perrone F, et al: Gemvin III: A phase III study of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) for stage IIIb or IV non-small cell lung cancer (NSCLC): An Italo-Canadian study. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1165)
36. Van Meerbeeck JP, Legrand C, van Klaveren RJ, et al: Chemotherapy for non-small cell lung cancer. Lancet 358:1271-1272, 2001
37. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning an amalgamation algorithms in 1,052 patients-The European Lung Cancer Working Party. J Clin Oncol 13:1221-1230, 1995
38. Jiroutek M, Johnson D, Blum R, et al: Prognostic factors in advanced non-small-cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc Am Soc Clin Oncol 17:461, 1998 (abstr 1774)
39. Billingham LJ, Cullen MH: The benefits of chemotherapy in patients subgroups with unresectable non-small cell lung cancer. Ann Oncol 12:1671-1675, 2001
40. Sweeney CJ, Zhu J, Sandler AB, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594. Cancer 92:2639-2647, 2001
41. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
42. Yamamoto N, Fukuoka M, Nakagawa K, et al: Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): A West-Japan Thoracic Oncology Group (WJTOG) study. Ann Oncol 11:S107, 2000 (abstr)
43. Smith IE, O'Brian MER, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
44. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002